Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.

Nguyen L, Fifis T, Malcontenti-Wilson C, Chan LS, Costa PN, Nikfarjam M, Muralidharan V, Christophi C.

BMC Cancer. 2012 Nov 15;12:522. doi: 10.1186/1471-2407-12-522.

2.

Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.

Fifis T, Nguyen L, Malcontenti-Wilson C, Chan LS, Nunes Costa PL, Daruwalla J, Nikfarjam M, Muralidharan V, Waltham M, Thompson EW, Christophi C.

Cancer Med. 2013 Oct;2(5):595-610. doi: 10.1002/cam4.109. Epub 2013 Aug 18.

3.

Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.

Malcontenti-Wilson C, Chan L, Nikfarjam M, Muralidharan V, Christophi C.

J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e96-e104. Epub 2007 Jun 7.

PMID:
17559382
4.

Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.

Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C.

Anticancer Res. 2007 Jul-Aug;27(4B):2317-23.

5.

Alterations in vascular architecture and permeability following OXi4503 treatment.

Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C.

Anticancer Drugs. 2008 Jan;19(1):17-22.

PMID:
18043126
6.

Styrene maleic acid copolymer-pirarubicin induces tumor-selective oxidative stress and decreases tumor hypoxia as possible treatment of colorectal cancer liver metastases.

Daruwalla J, Greish K, Malcontenti-Wilson C, Muralidharan V, Maeda H, Christophi C.

Surgery. 2015 Jul;158(1):236-47. doi: 10.1016/j.surg.2015.03.019. Epub 2015 May 18.

PMID:
25999256
7.

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.

Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, Edvardsen K.

Int J Cancer. 2004 Sep 10;111(4):604-10.

8.

Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW.

Microvasc Res. 2011 Jan;81(1):44-51. doi: 10.1016/j.mvr.2010.10.003. Epub 2010 Oct 23.

9.

Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling.

Zhang Q, Bai X, Chen W, Ma T, Hu Q, Liang C, Xie S, Chen C, Hu L, Xu S, Liang T.

Carcinogenesis. 2013 May;34(5):962-73. doi: 10.1093/carcin/bgt027. Epub 2013 Jan 27.

PMID:
23358852
10.

Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.

Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC, Su WY, Wang JL, Cui Y, Wang ZH, Fang JY.

J Biol Chem. 2012 Feb 17;287(8):5819-32. doi: 10.1074/jbc.M111.295964. Epub 2011 Dec 28.

11.

Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells.

Zhang P, Liu H, Xia F, Zhang QW, Zhang YY, Zhao Q, Chao ZH, Jiang ZW, Jiang CC.

Int J Mol Med. 2014 Jan;33(1):151-9. doi: 10.3892/ijmm.2013.1538. Epub 2013 Oct 30.

PMID:
24173500
12.

Inhibitory action of pristimerin on hypoxia‑mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells.

Zuo J, Guo Y, Peng X, Tang Y, Zhang X, He P, Li S, Wa Q, Li J, Huang S, Xu D.

Oncol Rep. 2015 Mar;33(3):1388-94. doi: 10.3892/or.2015.3708. Epub 2015 Jan 7.

PMID:
25571882
13.
14.

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.

Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ, Edvardsen K.

Anticancer Res. 2003 Mar-Apr;23(2B):1433-40.

PMID:
12820406
15.

Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-κB/microRNA 448 circuit.

Mak KK, Wu AT, Lee WH, Chang TC, Chiou JF, Wang LS, Wu CH, Huang CY, Shieh YS, Chao TY, Ho CT, Yen GC, Yeh CT.

Mol Nutr Food Res. 2013 Jul;57(7):1123-34. doi: 10.1002/mnfr.201200549. Epub 2013 Mar 15.

PMID:
23504987
16.

Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis.

Pan Y, Zhong LJ, Zhou H, Wang X, Chen K, Yang HP, Xiaokaiti Y, Maimaiti A, Jiang L, Li XJ.

Acta Pharmacol Sin. 2012 Jun;33(6):798-808. doi: 10.1038/aps.2012.42.

17.

Leukemia regression by vascular disruption and antiangiogenic therapy.

Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR.

Blood. 2010 Sep 2;116(9):1539-47. doi: 10.1182/blood-2009-06-230474. Epub 2010 May 14.

18.

Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.

Salmon HW, Siemann DW.

Clin Cancer Res. 2006 Jul 1;12(13):4090-4.

19.

Zeb1 links epithelial-mesenchymal transition and cellular senescence.

Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC.

Development. 2008 Feb;135(3):579-88. doi: 10.1242/dev.007047.

20.

Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).

Cai YC, Zou Y, Ye YL, Sun HY, Su QG, Wang ZX, Zeng ZL, Xian LJ.

Invest New Drugs. 2011 Apr;29(2):300-11. doi: 10.1007/s10637-009-9366-x. Epub 2009 Dec 11.

PMID:
20012336

Supplemental Content

Support Center